LGALS1 and urothelial carcinoma: The aberrant expression of Gal-1 has been described in various tumor tissues, including GC, ovarian carcinoma, hepatocellular carcinoma (HCC), colon carcinoma, renal cell carcinoma, breast carcinoma, cholangiocarcinoma, squamous cell carcinoma of the head and neck, lung carcinoma, urothelial carcinoma, prostate carcinoma, Kaposi’s sarcoma, Hodgkin lymphoma, and glioblastoma multiforme, often associated with poor survival [47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68].